Compare Crispr Therapeutics AG (CRSP) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Samsara Inc — how do they compare? Crispr Therapeutics AG trades at $53.81 (market cap $5.23B), while Samsara Inc trades at $39.15 (market cap $23.49B). The key difference: Samsara Inc is far larger — about 4.5× Crispr Therapeutics AG's market cap, and Samsara Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | IOT | |
|---|---|---|
Market Cap | $5.23B | $23.49B |
Sector | Health | Technology |
52-Week High | $76.78 | $45.22 |
52-Week Low | $44.34 | $24.25 |
Enterprise Value | $3.65B | $22.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Samsara (IOT) trades at $38.77, down 2.73% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. Recent earnings beats and strong analyst consensus (77.8% buy ratings) support optimism, while the company projects revenue growth to $1.7B in 2026 with a return to profitability. The stock's high P/E of 403.2 reflects growth expectations amid expanding AI adoption in its connected operations platform.
Outlook remains positive with a consensus price target of $44.50, offering 14.8% upside, driven by execution on large customer growth and margin expansion. Key risks include high valuation sensitivity to earnings misses, competitive pressures in software, and macroeconomic impacts on operational spending. Institutional accumulation, such as Arrowstreet Capital's 77.1% stake increase in Q1 2026, underscores confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
